E 6011

Drug Profile

E 6011

Alternative Names: E6011; KANAb001

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KAN Research Institute
  • Developer EA Pharma; Eisai Co Ltd
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Chemokine CX3CL1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary biliary cirrhosis; Rheumatoid arthritis
  • Phase I/II Crohn's disease

Most Recent Events

  • 13 Jul 2017 Eisai completes a phase I/II trial in Rheumatoid arthritis in Japan (SC) (NCT02196558)
  • 14 Jun 2017 Adverse events, efficacy, pharmacokinetics data from a phase I/II trial in Rheumatoid arthritis at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 02 Feb 2017 Phase-II clinical trials in Primary biliary cirrhosis in Japan (IV) (Eisai and EA Pharma pipelines, February 2017) (JapicCTI173515)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top